Plazma lipoproteinleri ve koroner kalp hastalığı

1. Ailhaud G. Adipose cell differention: a long way tipperary. In: Angel A, Anderson H, Bouchard C, Lau D, Leiter L, Mendelson R, eds. London, John Libbery & Co. Ltd, 1996: 3¬11.
2. Lamarshe B, Despres JP, Moorjani S, Cantin B, Degenais GR, Lupien JR. Prevalence of dyslipidemic phenotypes in ischemic heart disease. Am J Cardiol 1995; 75: 1189-95.
3. Davis B, Ashton WD, Rowlands DJ, El-Sayed M, Wallace PC, Duckett K, Coley J, Daggett AM. Association of conventional and exertional coronary heart disease risk factors in 5.000 apparently healthy men. Clin Cardiol 1996; 19: 303-8.
4. Colditz GA, Wolf AM. The public health impact of obesity. In: Angel A, Anderson H, Bouchard C, Lau D, Leiter L, Mendelson R, eds. London, John Libbery & Co. Ltd, 1996:
517-23.
5. Matsuzawa Y, Nakamura T, Shimomura I, Kotani K. Visceral fat accumulation and cardiovascular disease. In: Angel A, Anderson H, Bouchard C, Lau D, Leiter L, Mendelson R, eds.
London, John Liberty & Co, Ltd. 1996: 569-572.
6. Consensus statement. Detection and management of lipid disorders in diabetes mellitus. Diabetes Care 1996; 19: 96-102.
7. Lewis GF, Steiner G. Hypertriglyceridemia and its metabolic consequences as a risk factor for atherosclerotic cardiovascular disease in non-insulin-dependent diabetes mellitus. Diabetes 1996; 12: 36-56.
8. McInnes GT. Hypertension and coronary artery disease: cause and effect. J Hypertension 1995; 13: S49-S51
9. Siekmeier R, Wiilfroth P, Wieland H, Gross W, Mârz W. Low-density lipoprotein susceptibility to in vitro oxidation in healthy smokers and nonsmokers. Clin Chem 1996; 42: 524¬30.
10. Sanz EJ, Cazzuro AM, Bellido AL, Martin IML. Cigarette
consumption and lipoprotein (a) concentrations. Clin Chem 1996; 42: 479.
11. Wang XL, Sim AS, Badenhop RF, McCredie RM, Wilken DEL. A smoking-dependent risk of coronary artery disease associated with polymorphism of the endothelial nitric oxide
synthese gene. Natr Med 1996; 2: 41-5.
12. Jenner JL, Ordovas JM, Lemon-Fava S, Shaeffer MM, Wilson WF, Castelli WP, Schaffer EJ. Effects of age, sex and menopausal status of on plasma lipoprotein (a) levels: The Framingham Offspring study. Circulation 1993; 87: 1135-41.
13. Carmena R, Lussier-Cacan S, Roy M, Minnic A, Lingenhel A, Kronenberg F, Davignon J. Lp(a) levels and atherosclerotic vascular disease in a sample of patients with familial hypercholesterolemia sharing the same gene defect. Arterioscler Thromb Vasc Biol 1996; 16: 129-36.
14. Stampfer MJ, Sacks FM, Salvini S, Willent WC, Hennekens
CH. A prospective study of cholesterol, apolipoproteins and the risk of myocardial infarction. N Engl J Med 1991; 325:
373-81.
15. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H,
Seidel D. Lipoprotein Lp(a) as a predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: result from the Gottingen Risk Incidence an
Prevalence Study (GRIPS). Eur J Clin Invest 1994; 24: 444-53.
16. Genest J Jr, McNamara JR, Ordovas JM, Jenner JL, Siberman
SR, Anderson KM, Wilson PWF, Salem DN, Schaefer EJ.
Lipoprotein cholesterol, apolipoprotein A-1 and B and lipoprotein (a) abnormalities in men with premature coronary
artery disease. J Am Coll Cardiol 1992; 19: 792-882.
17. Van De Loo J. Circulating factors of the haemostatic systems as indicators of increased or reduced coronary risk. Br J
Haematology 1995; 91: 777-82.
18. Gonzales-Gronow M, Edelberg JM, Pizzo SV. Further characterization of the cellular plasminogen binding site: Evidence that plasminogen 2 and lipoprotein (a) compete for the same site. Biochemistry 1989; 28: 2374-7.
19. Liu J, Harpel PC, Pannel R, Gurewich V. Lipoprotein (a): a kinetic study of its influence on fibrin dependent plasminogen activation by prourokinase or tissue plasminogen activator.
Biochem 1993; 32: 9694-700.
20. Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM,
Williams RR. Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1996; 16: 250-5.
21. Breimer LH, Wannamethee G, Ebrahim S, Shaper AG. Serum bilirubin and risk factors of ischemic heart disease in middle-
aged British men. Clin Chem 1995; 41: 1504-8.
22. Wu TW, Wu J, Li RK, Mickle D, Carey D. Albumin-bound
bilirubins protect human ventricular monocytes against oxyradical damage. Biochem Cell Biol 1991; 69: 683-8.
23. Egerton W, Silberberg V, Crooks R, Ray C, Xie L. Dudman N. Serial measures, of plasma homocyst(e)ine after myocardial
infarction. Am J Cardiol 1996; 77: 759-61.
24. Stamper MJ, Malinow MR, Willet WC, Newcome LM, Upson MR, Ulmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial
infarction in US physicians. JAMA 1992; 268: 877-89.
25. Braun SL, Baum H, Neumayer D, Dogt W. Troponin T and troponin I after coronary bypass grafting: discordant results in patients with renal failure. Clin Chem 1996; 42: 782-84.
26. Rader DJ, Brewer HB. Lipoprotein (a): clinical apporach to a unique atherogenic lipoprotein. JAMA 1992; 267:1109-12.
27. Mayes PA. Lipid transport and storage. In: Murray RK, Graner DK, Mayes PA, Rodwell VW, eds. Harpers Biochemistry.
Appletion & Lange, 1996:254-70.
28. Gaubatz JW, Ghanem KI, Guavera J Jr, Nava ML, Patsch W,
Morrisett JD. Polymorphic forms of human apolipoprotein (a):
316
Turgut Özal Tıp Merkezi Dergisi 4(3): 1997
et al.
Plasma lipoproteins and coronary heart disease
inheritance and relationship of their molecular weights to plasma levels of lipoprotein (a). J Lipid Res 1990; 31: 603-13.
29. Loscalzo J. Lipoprotein (a). A unique risk factor for athero-thrombotic disease. Atherosclerosis 1990; 10: 672-79.
30. Boerwinkle E, Leffert CC, Lin J. Apolipoprotein (a) gene accounts for greater than 90% of the variation in plasma lipoprotein (a) concentrations. J Clin Invest 1992; 90: 52-60.
31. Whitby LG, Smith AF, Beckett GJ, Walker SW. Lecture notes on clinical Biochemistry. Blackwell Scientific Publicans,
1993:183-94.
32. Tomlison JE, McLean JW, Lawn RM. Rhesus monkey apolipo-protein (a): Sequence evolution and site of synthesis. J
Biol Chem 1989; 269: 5957-65.
33. Krempler F, Kostner GM, Rascher A, Haslauer F, Bolzano K, Sandhofer F. Studies on the role of specific cell surface receptors in the removal of lipoprotein (a) in man. J Clin Invest 1983; 71: 1431-41.
34. Utermann G, Hoplicker F, Dieplinger H, Seed M, Thompson G, Boerwinkle E. Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: multiplicative interaction of two gene loci associated with premature
atherosclerosis. Proc Natl Acad Sci USA 1989; 86: 4171-4.
35. Rath M, Niendorf A, Reblen T, Dietel M, Krebber HJ,
Beisiegel U. Detection and quantification of lipoprotein (a) on the arterial wall of 107 coronary by pass patients.
Arteriosclerosis 1989; 9: 579-92.
36. Cushing GL, Gaubatz JW, Nava ML, Burdick BJ, Bocan TMA, Guyton JR, Weilbaecher D, DeBakey ME, Lawrie GM,
Morrisett JD. Quantitation and localization of apolipoproteins A and B in coronary artery bypass vein grafts respected at reoperation. Atherosclerosis 1989; 9: 593-603.
37. Lip GYH, Jones AF. Lipoprotein (a) and vascular disease: thrombo-genesis and atherosclerosis. Q J Med 1995; 88: 529¬39.
38. Marcoviva SM, Albers JJ, Jacobs Jr DR, Perkins LL, Lewis CE, Howard BV, Savage P. Lipoprotein (a) concentrations and apolipoprotein (a) phenotypes in Caucasians and African Americans, the CARDIA study. Arterioscler Thromb 1993; 13:
1037-45.
39. Scott J. Thrombogenesis linked to atherogenesis at last? Nature
1989; 341: 22-3.
40. Stubbs P, O'Connor B, Noshirwani K, Seed M. Changes in lipoprotein (a) [Lp(a)] concentration in the peri- and postmyocardial infarction period. Eur Heart J 1991; 12(Suppl):
780.
41. Collen D, Lijnen HR. Molacular basis of fibrinolysis as relevant for thrombolytic therapy. Thrombosis and
Haemostasis 1995; 74: 167-71.
42. Rouy D, Laplaud M, Soboureau M, Angeles-Cano E. Hedgehog lipoprotein (a) is modulator of activation of plasminogen at the fibrin surface. Atheroscler Thromb 1992;
12: 146-54.
43. Edelberg JM, Gonzales-Gronow M, Pizzo SV. Lipoprotein (a) inhibits streptokinase mediated activation of human plasminogen. Biochemistry 1989; 28: 2370-4.
44. Howward GC, Pizzo SW. Lipoprotein (a) and its role in athero-thrombotic disease. Lab Invest 1993; 69: 373-86.
45. Aznar J, Estelles A, Breto M, Espana F, Alos T. Euglobulin clot lysis induced by tissue-type plasminogen activator is reduced with increased levels of lipoprotein (a). Thromb Res
1992; 66: 569-82.
46. Ross R. Atherosclerosis, on overview. In: Haber E, ed. Scientific American molecular cardiovascular medicine. New York, Scientific American Inc.1995: 11-30.
47. Brunelli C, Spalarossa P, Bertolini S, Balbi M, Barbara C, Masturzo P, Lantieri PB, Pastorini C. Lipoprotein (a) is increased in acute coronary syndromes (unstable angina pectoris and myocardial infarction), but it's not predictive of severity of coronary lesions. Clin Cardiol 1995; 18: 526-9.
48. Schreiner PJ, Heiss G, Tyroler HA, Morrisett JD, Davis CE,
Smith R. Race and gender differences in the association of Lp(a) with carotid artery wall thickness. Arterioscler Thromb Vasc Biol 1996; 16: 471-8.
49. Stiel GM, Reblin T, Bührlen M, Lattermann A, Nienaber CA. Differences in lipoprotein (a) and apolipoprotein (a) levels in men and women with advanced coronary atherosclerosis. Coronary Artery Disease 1995; 6: 347-50.
50. Soma MR, Paoletti R.Lipids and menopause. Cardiovasc Rev Reports 1995; 16: 15-21.
51. Sandholzer C, Boerwinkle E, Saha N, Tong MC, Utterman G. Apolipoprotein (a) phenotypes, Lp(a) concentration and plasma lipid levels in relation and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo (a) gene in coronary heart disease. J Clin Invest 1992; 89: 1040-6.
52. Wiklund O, Angelin B, Olofsson S-O, Ericson M, Fager G, Berglund L, Bondjers G. Apolipoprotein (a) and ischaemic heart disease in familial hypercholesterolemia. Lancet 1990;
335: 1360-3.
53. Seed M, Hoppichler F, Raeveley D, McCarthy S, Thomson GR, Boerwinkle E, Uterman G. Relation serum lipoprotein (a) concentration and apolipoprotein (a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990; 322: 1494-9.
54. Schumm DE. Essential of Biochemistry. Little Brown Co,
1995: 218.
55. Abeles RH, Frey PA, Jencks WP. Biochemistry. Jones &
Barlett Inc. 1992: 739-61.
56. Shefererd J. Danazol and plasma lipoprotein metabolism.
Intern J Gynecol Obstetr 1995; 50(Suppl): S23 -S26.
57. Aranow WS, Ahn C. Risk factors for new coronary events in a large cohort of very elderly patients with and without coronary artery disease. Am J Cardiol 1996; 77: 864-86.
58. Braunwald E. Cellular and molecular biology of cardiovascular disease. In Isselbacher KJ, Braunwald E, Wilson ED, Martin JB, Fauci AS, Kasper DL. Harrison's Principles of Internal Medicine. McGraw Hill, 1994; 1: 945.
59. Pocock SJ, Sharper AG, Philips AN, Walker M, Whitehead
TP. High density lipoprotein cholesterol is not a major risk factor for ischemic heart disease in British men. Br Med J 1986; 292: 525-9.
60. Castelli WP, Garrison RJ, Wilson PWF, Abott RD, Alousdian
S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham study. JAMA 1986; 256: 2835-8.
Journal of Turgut Özal Medical Center 4(3):1997
317
Plazma lipoproteinleri ve koroner kalp hastalıkları
A. Çığlı ve ark.
61. Abott RD, Wilson PWF, Cannel WP, Castelli WP. High
density lipoprotein cholesterol, total cholesterol screening and myocardial infarction- The Framingham study. Atherosclerosis 1988; 8: 207-11.
62. Enas EA, Yusuf S, Mehta JL. Prevalence of coronary artery disease in Asian Indians. Am J Cadiol 1992; 70: 945-9.
63. Lewis GF, Stainer G. Hypertriglyceridemia and its metabolic consequences as a risk factor for atherosclerotic cardiovascular disease in non-insulin dependent diabetes mellitus. Diabetes 1996; 12: 36-56.
64. Brinton EA. Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-1 and lowers hepatic lipase activity without lowering the fractional catabolic rate.
Arterioscler Thromb Vasc Biol 1996; 16: 431-40.
65. Drexel H, Aman FW, Rentsch K, Neuenschwander S, Luethy A, Khan SI, Follath F. The relation of the level of high density lipoprotein subfractions to the presence and extent of coronary
artery disease. Am J Cardiol 1992; 70: 436-40.
66. Buring JE, O'Connor GT, Goldhaber SZ, Rosner B. Herbert
PN, Blum CB, Breslow JL, Hennekens CH, Decreased HDL2
and HDL3 cholesterol, apo A-I, apo A-II and increased risk of myocardial infarction. Circulation 1992; 85: 22-9.
67. Hussain MM, Kancha RK, Zhou Z, Luchoomun J, Zu H, Bakillah A. Chylomicron assembly and catabolism: role of apolipoproteins and receptors. Biochim Biophys Acta 1996; 1300: 151-70.
68. Kriger M. Lipoprotein receptors and athersclerosis. In Haber, ed. Scientific American Inc. 1995: 31-47.
69. Stain EA, Myers GL. Lipids, apolipoproteins, and lipoproteins. In: Burtis CA, Ashwood ER, eds. Tietz Fundamentals of Clinical Chemistry. W.B. Saunders Company, 1996: 375-401.
70. Champe PC, Harvey RA. Lippincott Illustrated Revievs: Biochemistry. Philadelphia, J.B. Lippicott Co, 1994: 205-28.
71. Nakamura H, Ikewaki K, Nishivaki M, Shige H. Postprandial hyperlipidemia and coronary artery disease. Ann NY Acad Sci 1995; 748: 441-6.
72. Mamo JCL, Wheeler JR. Chylomicrons or their remnants penetrate rabbit thoracic aortas efficiently as do smaller macromolecules including low density lipoprotein, high density lipoprotein and albumin. Coronary Artery Dis 1994; 5:
695-705.
73. Weintraub MS, Glasskopf I, Rassin T, Miller H, Charach G,
Rotmensch HH, Liron M, Rubistein A, Iaina A. Clearence of chylomicron remnants in normolipidemic patients with coronary artery disease: case control study over three years.
BMJ 1996; 13: 936-9.
74. Proctor SD, Mamo JCL. Arterial fatty lesions have increased uptake of chylomicron remnants but not low density lipoproteins. Coronary Artery Dis 1996; 7: 239-45.
75. Yu KC-W. Mamo JCL. Killing of arterial muscle cell by chylomicron remnants. Biochem Biophys Res Com 1996; 220:
68-71.
76. Souza DRS, Maranhao RC, Varella-Carcia M, VilafanhaD, Santos AB, Pileggi F, da Luz PL. Postprandial levels of lipiprotein (a) in subject with or without coronary artery disease. Intern J Cardiol 1996; 53: 94-6.
77. Sehayek E, Eisenberg S. The role of native apolipoprotein B-containing lipoproteins in atherosclerosis: celluler mechanism. Curr Opin Lipidiol 1994; 5: 350-3.
78. Natio HK. Coronary artery disease and disorders of lipid metabolism. In: Kaplan LA, Pence AJ, eds. Clinical Chemistry, Mosby Publishing, 1996: 642-82.
79. Pantier PC, CopeJY, Smith JL. Appendix. In: Burtis CA,
Aswood ER, eds. Tietz Fundamentals of Clinical Chemistry,
W.B. Saunders Co. 1996: 766-830.